These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 11602729

  • 21. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, Newman A, Ouyang YB, Haynes BF, Verkoczy L.
    J Immunol; 2013 Aug 01; 191(3):1260-75. PubMed ID: 23825311
    [Abstract] [Full Text] [Related]

  • 22. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Conley AJ, Kessler JA, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, Emini EA.
    Proc Natl Acad Sci U S A; 1994 Apr 12; 91(8):3348-52. PubMed ID: 7512731
    [Abstract] [Full Text] [Related]

  • 23. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
    Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT.
    J Virol; 2011 Aug 12; 85(16):8217-26. PubMed ID: 21653673
    [Abstract] [Full Text] [Related]

  • 24. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
    Montero M, van Houten NE, Wang X, Scott JK.
    Microbiol Mol Biol Rev; 2008 Mar 12; 72(1):54-84, table of contents. PubMed ID: 18322034
    [Abstract] [Full Text] [Related]

  • 25. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
    Franquelim HG, Chiantia S, Veiga AS, Santos NC, Schwille P, Castanho MA.
    AIDS; 2011 Feb 20; 25(4):419-28. PubMed ID: 21245727
    [Abstract] [Full Text] [Related]

  • 26. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD.
    J Virol; 2004 Oct 20; 78(19):10724-37. PubMed ID: 15367639
    [Abstract] [Full Text] [Related]

  • 27. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
    Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.
    J Virol; 2006 Feb 20; 80(4):1680-7. PubMed ID: 16439525
    [Abstract] [Full Text] [Related]

  • 28. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
    Gustchina E, Bewley CA, Clore GM.
    J Virol; 2008 Oct 20; 82(20):10032-41. PubMed ID: 18667502
    [Abstract] [Full Text] [Related]

  • 29. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
    Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS.
    PLoS One; 2012 Oct 20; 7(9):e44241. PubMed ID: 22970187
    [Abstract] [Full Text] [Related]

  • 30. Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.
    Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, Hanson CV, Bomsel M, Mor TS.
    Curr HIV Res; 2008 May 20; 6(3):218-29. PubMed ID: 18473785
    [Abstract] [Full Text] [Related]

  • 31. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR, Strick N, Lin K, Jiang S.
    AIDS Res Hum Retroviruses; 1995 Jun 20; 11(6):687-96. PubMed ID: 7576928
    [Abstract] [Full Text] [Related]

  • 32. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S.
    J Virol; 2000 Aug 20; 74(15):7096-107. PubMed ID: 10888650
    [Abstract] [Full Text] [Related]

  • 33. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM.
    Science; 2005 Jun 24; 308(5730):1906-8. PubMed ID: 15860590
    [Abstract] [Full Text] [Related]

  • 34. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
    Bryson S, Julien JP, Hynes RC, Pai EF.
    J Virol; 2009 Nov 24; 83(22):11862-75. PubMed ID: 19740978
    [Abstract] [Full Text] [Related]

  • 35. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.
    Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK.
    J Virol; 2012 Mar 24; 86(6):2930-41. PubMed ID: 22238313
    [Abstract] [Full Text] [Related]

  • 36. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.
    J Virol; 2006 Mar 24; 80(6):3030-41. PubMed ID: 16501112
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Bjorkman PJ.
    Proc Natl Acad Sci U S A; 2009 May 05; 106(18):7385-90. PubMed ID: 19372381
    [Abstract] [Full Text] [Related]

  • 39. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.
    J Virol; 2004 Dec 05; 78(23):13232-52. PubMed ID: 15542675
    [Abstract] [Full Text] [Related]

  • 40. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
    Finnegan CM, Berg W, Lewis GK, DeVico AL.
    J Virol; 2002 Dec 05; 76(23):12123-34. PubMed ID: 12414953
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.